Proteomtech, Inc.

Costa Mesa, CA 92626

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $1.15MM
First Award Date 08/01/03
Most Recent Award Date 09/29/06

Key Personnel

Last Name Name Awards Contact
Lin Xinli Lin 1
Medynski Daniel C Medynski 4
Lin Xlnli Henry Lin 1

6 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 09/29/06 - 09/30/07

DESCRIPTION (provided by applicant): Thrombolytic treatment with plasminogen activators (PA) such as tissue plasminogen activator (tPA) has been used not only for treatment of acute myocardial infarction, but also peripheral arterial occlusion (PAO). However, the risk of life-threatening intracranial hemorrhage is measurably high (0.4-2.9%), par...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/05 - 07/31/06

DESCRIPTION (provided by applicant): Blocking or inhibiting tumor blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial Growth Inhibitor (VEGI; TNFSF-15) secreted from human endothelial cells have demonstrated that it is a potent negative regulator of angiogenesis th...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/04 - 07/31/05

DESCRIPTION (provided by applicant): Blocking or inhibiting tumor blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial Growth Inhibitor (VEGI; TNFSF-15) secreted from human endothelial cells have demonstrated that it is a potent negative regulator of angiogenesis th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/17/04 - 11/16/04
PI: Xinli Lin

DESCRIPTION (provided by investigator): Chronic infection with hepatitis B virus (HBV) is associated with a high incidence of liver diseases, including hepatocellular carcinoma (HCC). Hepatitis B virus x antigen (HBxAg), one of the four proteins encoded by the virus, stimulates virus gene expression and replication, and is crucial for the establ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/04 - 06/30/04

DESCRIPTION (provided by applicant): The objective of this proposal is to bioengineer a mutant variant of prourokinase (proUK) with improved therapeutic properties for treatment of acute myocardial infarction(AMI). ProUK is unique among thrombolytic agents in that it is stable as an inert zymogen in blood plasma before activation and conversion ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/03 - 01/31/04

DESCRIPTION (provided by applicant): Blocking or inhibiting blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial Growth Inhibitor (VEGI; TNFSF-15) secreted from human endothelial cells have demonstrated that it is a potent negative regulator of angiogenesis that induce...